ketamine
Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)
"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."
opioid use disorder
Spotlight: Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression (Manza, et al, 2025)
Ketamine was safe and generally well-tolerated. At 10-day follow-up post-ketamine infusions, participant acceptability ratings were mostly favorable. 3-month timepoint - strong treatment adherence with self-reported depression symptoms decrease
ketamine
Spotlight: Intravenous ketamine for suicide ideation in borderline personality and depression (Bachir, et al, 2025)
"This report highlights ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles where traditional treatments like electroconvulsive therapy often fail. "
ketamine
Spotlight: A retrospective analysis of ketamine intravenous therapy for post-traumatic stress disorder in real-world care settings (McInnes, et al, 2025)
"In a large real-world sample of 8,136 PTSD patients (87 % with comorbid depression), Ketamine Intravenous Therapy (KIT) significantly reduced PTSD and depression symptoms."
ketamine
Spotlight: The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression (2025)
"The reductions in right LB volumes correlate with better clinical responses to ketamine in patients with TRD, suggesting ketamine may exert its effect by attenuating amygdalar overactivity in this population."
ketamine
Spotlight: Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder (Haikazian, et al, 2025)
"Ketamine was determined to be relatively safe, with zero cases of suicidal behaviour and addiction behaviour throughout treatment."
ketamine
Spotlight "Prefrontal contribution to passive coping behaviour in chronic stress and treatment by fast-acting antidepressant" (Fong, et al, 2025)
"Persistent passive coping (p-coping) behaviour is a hallmark feature in major depression and is reversed by fast-acting antidepressants (such as ketamine)."
iv ketamine
Spotlight: "Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study" (Singh, et al, 2025)
Observational study provides evidence regarding longer durability of generic IV ketamine compared to intranasal esketamine (Spravato).
ketamine therapy
Revisiting Ketamine (after 5 years)
A lot has changed in my life since my first ketamine journey...
at home ketamine
Spotlight: Ketamine Lit Review on Mastodon (a site not owned by fascists)
Over 800 posts to date! See what's new in ongoing ketamine research spanning over 60 years.
psychedelics
Neural correlates and subjective experiences in meditation vs psychedelics, including ketamine (Preliminary Lit Review)
A preliminary, evolving review of the literature. (Ongoing Draft) | Psychedelic Institute of Mental Health & Family Therapy
at-home ketamine
Increasing Access to Psychedelic-Assisted Psychotherapy : The "proliferation of ketamine clinics" narrative and cost considerations
Psychedelic and psychiatric medicines have been studied for over 100 years as adjuncts to psychotherapy, with over 60 years of ongoing research on the off-label use of racemic ketamine, a generic medicine in various routes of administration with varying levels of support care
ketamine-assisted psychotherapy
Sublingual & Oral Ketamine Research: Efficacy, Dosage, and Treatment for Mental Health
Ongoing review of the literature related to safety and efficacy of ketamine and esketamine by mouth.
